Özlem Türeci

Özlem Türeci in 2019 Özlem Türeci (; born 6 March 1967) is a German physician, scientist and entrepreneur. In 2008, she co-founded the biotechnology company BioNTech, which in 2020 developed the first messenger RNA-based vaccine approved for use against COVID-19. Türeci has served as BioNTech's chief medical officer since 2018. Since 2021, she has been Professor of Personalized Immunotherapy at the Helmholtz Institute for Translational Oncology (HI-TRON) and Johannes Gutenberg University Mainz. Türeci and her spouse, Uğur Şahin, have won a number of awards. Provided by Wikipedia
Showing 1 - 20 results of 20 for search 'Özlem Türeci', query time: 0.05s Refine Results
  1. 1
    Racing for a SARS‐CoV‐2 vaccine

    Racing for a SARS‐CoV‐2 vaccine by Özlem Türeci, Uğur Şahin

    Published 2021-09-01
    Get full text
    Article
  2. 2
    Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination

    Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination by Mathias Vormehr, Barbara Schrörs, Sebastian Boegel, Martin Löwer, Özlem Türeci, Ugur Sahin

    Published 2015-01-01
    Get full text
    Article
  3. 3
    Addressing COVID-19 vaccine hesitancy

    Addressing COVID-19 vaccine hesitancy by George Kassianos, Joan Puig-Barberà, Hannah Dinse, Martin Teufel, Özlem Türeci, Shanti Pather

    Published 2022-06-01
    Get full text
    Article
  4. 4
    Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity

    Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity by Tana A. Omokoko, Uli Luxemburger, Shaheer Bardissi, Petra Simon, Magdalena Utsch, Andrea Breitkreuz, Özlem Türeci, Ugur Sahin

    Published 2016-01-01
    Get full text
    Article
  5. 5
    Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data

    Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data by Frank van den Ouweland, Nicola Charpentier, Özlem Türeci, Ruben Rizzi, Federico J. Mensa, Claudia Lindemann, Shanti Pather

    Published 2024-12-01
    Get full text
    Article
  6. 6
    SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines

    SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines by Shanti Pather, Shabir A. Madhi, Benjamin J. Cowling, Paul Moss, Jeremy P. Kamil, Sandra Ciesek, Alexander Muik, Özlem Türeci

    Published 2023-05-01
    Get full text
    Article
  7. 7
    Corrigendum: SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines

    Corrigendum: SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines by Shanti Pather, Shabir A. Madhi, Benjamin J. Cowling, Paul Moss, Jeremy P. Kamil, Sandra Ciesek, Alexander Muik, Özlem Türeci

    Published 2023-06-01
    Get full text
    Article
  8. 8
    Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide

    Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide by Jens Schumacher, Tijana Bacic, René Staritzbichler, Matin Daneschdar, Thorsten Klamp, Philipp Arnold, Sabrina Jägle, Özlem Türeci, Jürgen Markl, Ugur Sahin

    Published 2018-04-01
    Get full text
    Article
  9. 9
    The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines

    The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines by Gary McLean, Jeremy Kamil, Benhur Lee, Penny Moore, Thomas F. Schulz, Alexander Muik, Ugur Sahin, Özlem Türeci, Shanti Pather

    Published 2022-04-01
    Get full text
    Article
  10. 10
    Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial

    Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial by Juleen Gayed, Vishva Bangad, Xia Xu, Federico Mensa, Mark Cutler, Özlem Türeci, Uǧur Şahin, Kayvon Modjarrad, Kena A. Swanson, Annaliesa S. Anderson, Alejandra Gurtman, Nicholas Kitchin

    Published 2024-07-01
    Get full text
    Article
  11. 11
    Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1

    Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1 by Alexander Muik, Jasmin Quandt, Bonny Gaby Lui, Maren Bacher, Sebastian Lutz, Maika Grünenthal, Aras Toker, Jessica Grosser, Orkun Ozhelvaci, Olga Blokhina, Svetlana Shpyro, Isabel Vogler, Nadine Salisch, Özlem Türeci, Ugur Sahin

    Published 2024-08-01
    Get full text
    Article
  12. 12
    The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis

    The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis by Adrian Georg Simon, Su Ir Lyu, Mark Laible, Stefan Wöll, Özlem Türeci, Uğur Şahin, Hakan Alakus, Luca Fahrig, Thomas Zander, Reinhard Buettner, Christiane Josephine Bruns, Wolfgang Schroeder, Florian Gebauer, Alexander Quaas

    Published 2023-08-01
    Get full text
    Article
  13. 13
    Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody

    Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody by Hayat Bähr-Mahmud, Ursula Ellinghaus, Christiane R. Stadler, Leyla Fischer, Claudia Lindemann, Anuhar Chaturvedi, Jan Diekmann, Stefan Wöll, Imke Biermann, Bernhard Hebich, Caroline Scharf, Manuela Siefke, Alexandra S. Roth, Martin Rao, Kerstin Brettschneider, Eva-Maria Ewen, Uğur Şahin, Özlem Türeci

    Published 2023-12-01
    Get full text
    Article
  14. 14
    Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age

    Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine w... by Joel M. Neutel, Rahsan Erdem, Qin Jiang, Kevin Cannon, Helen Stacey, Ryan Newton, Emily Gomme, Wen Li, Federico J. Mensa, Özlem Türeci, Uğur Şahin, Kena A. Swanson, Iona Munjal, David Cooper, Kenneth Koury, Annaliesa S. Anderson, Alejandra Gurtman, Nicholas Kitchin

    Published 2025-02-01
    Get full text
    Article
  15. 15
    Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial

    Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial by Juleen Gayed, Oyeniyi Diya, Francine S. Lowry, Xia Xu, Vishva Bangad, Federico Mensa, Jing Zou, Xuping Xie, Yanping Hu, Claire Lu, Mark Cutler, Todd Belanger, David Cooper, Kenneth Koury, Annaliesa S. Anderson, Özlem Türeci, Uǧur Şahin, Kena A. Swanson, Kayvon Modjarrad, Alejandra Gurtman, Nicholas Kitchin

    Published 2024-01-01
    Get full text
    Article
  16. 16
    Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults

    Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults by Louise Murdoch, Karen Quan, James A. Baber, Agnes W. Y. Ho, Ying Zhang, Xia Xu, Claire Lu, David Cooper, Kenneth Koury, Stephen P. Lockhart, Annaliesa S. Anderson, Özlem Türeci, Uğur Şahin, Kena A. Swanson, William C. Gruber, Nicholas Kitchin, the C4591030 Clinical Trial Group

    Published 2023-09-01
    Get full text
    Article
  17. 17
    Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity

    Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity by Alexander Muik, Bonny Gaby Lui, Jasmin Quandt, Huitian Diao, Yunguan Fu, Maren Bacher, Jessica Gordon, Aras Toker, Jessica Grosser, Orkun Ozhelvaci, Katharina Grikscheit, Sebastian Hoehl, Niko Kohmer, Yaniv Lustig, Gili Regev-Yochay, Sandra Ciesek, Karim Beguir, Asaf Poran, Isabel Vogler, Özlem Türeci, Ugur Sahin

    Published 2023-08-01
    Get full text
    Article
  18. 18
    DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity

    DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity by Maria Jure-Kunkel, Homer C Adams III, Kate Sasser, Mark Fereshteh, Alexander Muik, Isil Altintas, Friederike Gieseke, Aras Toker, Özlem Türeci, Tahamtan Ahmadi, Ugur Sahin, Dennis Verzijl, Kristina B Schoedel, Jordan M Blum, Bianca Sänger, Saskia M Burm, Eliana Stanganello, Vanessa M Spires, Fulvia Vascotto, Juliane Quinkhardt, Mustafa Diken, David P E Satijn, Sebastian Kreiter, Esther C W Breij

    Published 2022-06-01
    Get full text
    Article
  19. 19
    Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial

    Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial by Ai-Min Hui, Jingxin Li, Li Zhu, Rong Tang, Huayue Ye, Mei Lin, Lei Ge, Xiyuan Wang, Fuzhong Peng, Zhenggang Wu, Xiling Guo, Yunfeng Shi, Hongxing Pan, Jiahong Zhu, Zhizhou Song, Jingjun Qiu, Wei Wang, Jianfei Zheng, Orkun Ozhelvaci, Svetlana Shpyro, Meghan Bushway, Evelyna Derhovanessian, Marie-Cristine Kühnle, Ulrich Luxemburger, Alexander Muik, Yoana Shishkova, Zakaria Khondker, Simin Hu, Eleni Lagkadinou, Uğur Şahin, Özlem Türeci, Fengcai Zhu

    Published 2022-12-01
    Get full text
    Article
  20. 20
    Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination

    Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination by Timothy E. Albertson, Caitlin Hansen, Smiti Bihari, Juleen Gayed, Xia Xu, J. Abraham Simón-Campos, Michael E. Dever, Jose F. Cardona, Essack Mitha, Jeffrey B. Baker, Georgina Keep, Islamiat Oladipupo, Federico J. Mensa, Ye Feng, Hua Ma, Kenneth Koury, Susan Mather, Claudia Ana Ianos, Annaliesa S. Anderson, Özlem Türeci, Uǧur Şahin, William C. Gruber, Alejandra Gurtman, Charu Sabharwal, Nicholas Kitchin, the C4591031, C4591007 Clinical Trial Groups

    Published 2024-03-01
    Get full text
    Article

Search Tools: